E authors has any conflicts of interest or any monetary ties to disclose. REFERENCES 1. Baek, N.N., Jang, H.R., Huh, W., Kim, Y.G., Kim, D.J., Oh, H.Y., and Lee, J.E. 2012. The role of nafamostat mesylate in continuous renal replacement therapy among patients at higher danger of bleeding. Ren Fail 34:279-285. Crosswell, A., Brain, M.J., and Roodenburg, O. 2014. Vascular access web site influences circuit life in continuous renal replacement therapy. Crit Care Resusc 16:127-130. Gando, S., Iba, T., Eguchi, Y., Ohtomo, Y., Okamoto, K., Koseki, K., Mayumi, T., Murata, A., Ikeda, T., Ishikura, H., Ueyama, M., Ogura, H., Kushimoto, S., Saitoh, D., Endo, S., and Shimazaki, S. 2006. A multicenter, potential validation of disseminated intravascular coagulation diagnostic criteria for critically ill individuals: comparing present criteria. Crit Care Med 34:625-31 Harris, D.G., Koo, G., McCrone, M.P., Scalea, T.M., Chiu, W.C., Diaz, J.J., and Lissauer, M.E. 2014. Recurrent kidney injury in critically ill surgical patients is frequent and linked with worse outcomes. J Trauma Acute Care Surg 76:1397-1401. Iwama, H., Watanabe, K., and Obara, S. 2003. In vitro connection involving the blood nafamostat concentration and activated coagulation time. Can J Anaesth 50:621-622. Kinnunen, E.M., Juvonen, T., Airaksinen, K.E., Heikkinen, J., Kettunen, U., Mariscalco, G., and Biancari, F. 2014. Clinical significance and determinants of your universal definition of perioperative bleeding classification in individuals undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 148:1640-1646 e1642. Levey, A.S., Stevens, L.A., Schmid, C.Formula of 37091-73-9 H.102879-42-5 Chemscene , Zhang, Y.PMID:34337881 L., Castro, A.F. 3rd, Feldman, H.I., Kusek, J.W., Eggers, P., Van Lente, F, Greene, T., and Coresh, J. 2009. A new equation to estimate glomerular filtration price. Ann Intern Med 150:604-612. Lewis, J.D., Shin, E.J., and Metz, D.C. 2000. Characterization of gastrointestinal bleeding in severely ill hospitalized patients. Crit Care Med 28:46-50. Makino, S., Egi, M., Kita, H., Miyatake, Y., Kubota, K., and Mizobuchi, S. 2016. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants in the course of continuous renal replacement therapy. Int J Artif Organs 39:16-21. Muckart, D.J., and Bhagwanjee, S. 1997. American College of Chest Physicians/Society of Important Care Medicine Consensus Conference definitions of your systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25:1789-1795. Oudemans-van Straaten, H.M., Wester, J.P., de Pont, A.C., and Schetz, M.R. 2006. Anticoagulation strategies in continuous renal replacement therapy: can the option be proof primarily based Intensive Care Med 32:188-202. Uchiba, M., Okajima, K., Abe, H., Okabe, H., and Takatsuki, K. 1994. Impact of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complicated activity. Thromb Res 74:155-161. Uchino, S., Bellomo, R., and Ronco, C. 2001. Intermittent versus continuous renal replacement therapy in the ICU: influence on electrolyte and acid-base balance. Intensive Care Med 27:1037-1043. Vincent, J.L., Moreno, R., Takala, J., Willatts, S., De Mendon , A., Bruining, H., Reinhart, C.K., Suter, P.M., and Thijs, L.G. 1996. The SOFA (sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf with the Functioning Group on Sepsis-related Challenges from the European Society of Intensive Care Medicine. Intensive Care Med 22: 707-10. Wu, M.Y.,.
